J&J, Pfizer, Takeda, Merck, Sanofi, Lilly, Janssen, Scripps Research Institute

– Johnson & Johnson isn’t lacking in pipeline power, boasting more than a dozen drugs in phase 3 trials or filed for regulatory approval. The Pipeline Power at Johnson & Johnson  from The Motley Fool takes a look at the company’s pipeline of pharmaceuticals in development that will power the future

– PMLiVE’s Pharma CEOs team up to tackle Alzheimer’s, covers the news that founding members of the Global CEO Initiative on Alzheimer’s Disease (CEOi) (including AC Immune, Lilly, Janssen, Merck & Co, Pfizer, Sanofi and GE Healthcare) will partner with other organizations, such as Nestle Health Science and Bank of America Merrill Lynch, to help address the “unprecedented global health, societal and fiscal threat” of the neurological condition

– The gross research budgets for the top 10 pharma companies in the world hit $70.37 billion in 2012, down slightly from $70.38 billion in 2011. FierceBiotech’s Biopharma’s Top R&D Spenders – 2012 reviews last year’s results, and offers an analysis of where they point

– In 2009 Pfizer became the first pharmaceutical company to earn AAHRPP accreditation for its phase I clinical research units. PharmaTimes reports Expanded Pfizer accreditation should have “global repercussions” for AAHRPP  after Pfizer expanded its AAHRPP recognition to cover all of the company’s Phase II to IV clinical trials earlier this month

– PharmaLive’s Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration, with the goal to expand their recent research collaboration to search for new drug targets for a variety of diseases. The new agreement extends an initial collaboration launched in 2010 between scientists on the Florida campus of TSRI and Envoy Therapeutics (Envoy was acquired by Takeda Pharmaceuticals last November) that led to several breakthroughs in identifying potential new compounds for neurological and psychiatric diseases